Progress in the discovery of selective, high affinity A2B adenosine receptor antagonists as clinical candidates View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2009-03

AUTHORS

Rao V. Kalla, Jeff Zablocki

ABSTRACT

The selective, high affinity A(2B) adenosine receptor (AdoR) antagonists that were synthesized by several research groups should aid in determining the role of the A(2B) AdoR in inflammatory diseases like asthma or rheumatoid arthritis (RA) and angiogenic diseases like diabetic retinopathy or cancer. CV Therapeutics scientists discovered the selective, high affinity A(2B) AdoR antagonist 10, a 8-(4-pyrazolyl)-xanthine derivative [CVT-6883, K(i)(hA(2B)) = 22 nM; K(i)(hA(1)) = 1,940 nM; K(i)(hA(2A)) = 3,280; and K(i)(hA(3)) = 1,070 nM] that has favorable pharmacokinetic (PK) properties (t (1/2) = 4 h and F > 35% rat). Compound 10 demonstrated functional antagonism at the A(2B) AdoR (K(B) = 6 nM) and efficacy in a mouse model of asthma. In two phase 1 clinical trials, CVT-6883 was found to be safe, well tolerated, and suitable for once daily dosing. A second compound 20, 8-(5-pyrazolyl)-xanthine, has been nominated for development from Baraldi's group in conjunction with King Pharmaceuticals that has favorable A(2B) AdoR affinity and selectivity [K(i)(hA(2B)) = 5.5 nM; K(i)(hA(1)) > 1,000 nM; K(i)(hA(2A)) > 1,000; and K(i)(hA(3)) > 1,000 nM], and it has been demonstrated to be a functional antagonist. A third compound 32, a 2-aminopyrimidine, from the Almirall group has high A(2B) AdoR affinity and selectivity [K(i)(hA(2B)) = 17 nM; K(i)(hA(1)) > 1,000 nM; K(i)(hA(2A)) > 2,500; and K(i)(hA(3)) > 1,000 nM], and 32 has been moved into preclinical safety testing. Since three highly selective, high affinity A(2B) AdoR antagonists have been nominated for development with 10 (CVT-6883) being the furthest along in the development process, the role of the A(2B) AdoR in various disease states will soon be established. More... »

PAGES

21-29

References to SciGraph publications

  • 2002-04. Targeting Adenosine Receptors in TREATMENTS IN RESPIRATORY MEDICINE
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s11302-008-9119-x

    DOI

    http://dx.doi.org/10.1007/s11302-008-9119-x

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1036195632

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/18568423


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1199", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Other Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "name": [
                "Department of Bioorganic Chemistry, CV Therapeutics Inc., 3172 Porter Drive, Palo Alto, CA 94304 USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Kalla", 
            "givenName": "Rao V.", 
            "id": "sg:person.01031733402.53", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01031733402.53"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "name": [
                "Department of Bioorganic Chemistry, CV Therapeutics Inc., 3172 Porter Drive, Palo Alto, CA 94304 USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Zablocki", 
            "givenName": "Jeff", 
            "id": "sg:person.0706532554.35", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706532554.35"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "https://doi.org/10.1016/j.bmc.2008.01.002", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1002966243"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1038/sj.bjp.0706272", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1003683098"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1038/sj.bjp.0706272", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1003683098"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1124/jpet.106.112250", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006292491"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/s0968-0896(98)00007-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009631944"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf03256599", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1015558318", 
              "https://doi.org/10.1007/bf03256599"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/j.bmcl.2008.01.008", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017151471"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/s0165-6147(98)01179-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017804473"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1161/01.hyp.0000144800.21037.a5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023073291"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1161/01.hyp.0000144800.21037.a5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023073291"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/s0968-0896(01)00201-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1024938586"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/(sici)1098-2299(199905)47:1<45::aid-ddr6>3.0.co;2-u", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027056941"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1165/rcmb.2003-0118oc", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027367284"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/j.bcp.2004.03.026", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027842212"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1165/rcmb.2004-0103oc", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041386031"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/j.bmcl.2004.03.084", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042039926"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1172/jci27303", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042274622"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/j.bmcl.2004.11.044", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1044434905"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1517/13543776.16.10.1347", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1046730538"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/j.bmcl.2006.04.074", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1049359839"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1124/mol.104.009225", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1049533071"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/(sici)1098-2299(199908)47:4<178::aid-ddr4>3.0.co;2-l", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1050303514"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/j.bmcl.2005.10.002", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052793565"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1021/cr0682195", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1053896200"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1021/cr0682195", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1053896200"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1021/jm00036a019", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1055933249"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1021/jm00083a018", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1055934504"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1021/jm00113a029", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1055935638"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1021/jm00382a018", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1055945659"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1021/jm0104318", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1055946702"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1021/jm0104318", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1055946702"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1021/jm011049y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1055946960"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1021/jm011049y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1055946960"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1021/jm0309654", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1055948364"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1021/jm0309654", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1055948364"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1021/jm051268+", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1055950062"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1021/jm051268+", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1055950062"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1021/jm061333v", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1055950894"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1021/jm061333v", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1055950894"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1021/jm7014815", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1055955364"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1021/jm7014815", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1055955364"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1021/jm990499b", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1055959662"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1021/jm990499b", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1055959662"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.2174/138955705774933374", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1069182582"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.2174/1568026033392264", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1069192897"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.2174/15680266106061375", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1069194448"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1074962052", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.4049/jimmunol.172.12.7726", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1076850170"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1083202690", 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2009-03", 
        "datePublishedReg": "2009-03-01", 
        "description": "The selective, high affinity A(2B) adenosine receptor (AdoR) antagonists that were synthesized by several research groups should aid in determining the role of the A(2B) AdoR in inflammatory diseases like asthma or rheumatoid arthritis (RA) and angiogenic diseases like diabetic retinopathy or cancer. CV Therapeutics scientists discovered the selective, high affinity A(2B) AdoR antagonist 10, a 8-(4-pyrazolyl)-xanthine derivative [CVT-6883, K(i)(hA(2B)) = 22 nM; K(i)(hA(1)) = 1,940 nM; K(i)(hA(2A)) = 3,280; and K(i)(hA(3)) = 1,070 nM] that has favorable pharmacokinetic (PK) properties (t (1/2) = 4 h and F > 35% rat). Compound 10 demonstrated functional antagonism at the A(2B) AdoR (K(B) = 6 nM) and efficacy in a mouse model of asthma. In two phase 1 clinical trials, CVT-6883 was found to be safe, well tolerated, and suitable for once daily dosing. A second compound 20, 8-(5-pyrazolyl)-xanthine, has been nominated for development from Baraldi's group in conjunction with King Pharmaceuticals that has favorable A(2B) AdoR affinity and selectivity [K(i)(hA(2B)) = 5.5 nM; K(i)(hA(1)) > 1,000 nM; K(i)(hA(2A)) > 1,000; and K(i)(hA(3)) > 1,000 nM], and it has been demonstrated to be a functional antagonist. A third compound 32, a 2-aminopyrimidine, from the Almirall group has high A(2B) AdoR affinity and selectivity [K(i)(hA(2B)) = 17 nM; K(i)(hA(1)) > 1,000 nM; K(i)(hA(2A)) > 2,500; and K(i)(hA(3)) > 1,000 nM], and 32 has been moved into preclinical safety testing. Since three highly selective, high affinity A(2B) AdoR antagonists have been nominated for development with 10 (CVT-6883) being the furthest along in the development process, the role of the A(2B) AdoR in various disease states will soon be established.", 
        "genre": "research_article", 
        "id": "sg:pub.10.1007/s11302-008-9119-x", 
        "inLanguage": [
          "en"
        ], 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1035517", 
            "issn": [
              "1573-9538", 
              "1573-9546"
            ], 
            "name": "Purinergic Signalling", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "5"
          }
        ], 
        "name": "Progress in the discovery of selective, high affinity A2B adenosine receptor antagonists as clinical candidates", 
        "pagination": "21-29", 
        "productId": [
          {
            "name": "readcube_id", 
            "type": "PropertyValue", 
            "value": [
              "ac6b80eab621568b006300f20fb413a736788294a96f2fd5632c4f4a81890b61"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "18568423"
            ]
          }, 
          {
            "name": "nlm_unique_id", 
            "type": "PropertyValue", 
            "value": [
              "101250499"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s11302-008-9119-x"
            ]
          }, 
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1036195632"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s11302-008-9119-x", 
          "https://app.dimensions.ai/details/publication/pub.1036195632"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2019-04-11T02:19", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8700_00000550.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721775/"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11302-008-9119-x'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11302-008-9119-x'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11302-008-9119-x'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11302-008-9119-x'


     

    This table displays all metadata directly associated to this object as RDF triples.

    193 TRIPLES      21 PREDICATES      68 URIs      21 LITERALS      9 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s11302-008-9119-x schema:about anzsrc-for:11
    2 anzsrc-for:1199
    3 schema:author Ncaab3614c2804d3da1391352540180e6
    4 schema:citation sg:pub.10.1007/bf03256599
    5 https://app.dimensions.ai/details/publication/pub.1074962052
    6 https://app.dimensions.ai/details/publication/pub.1083202690
    7 https://doi.org/10.1002/(sici)1098-2299(199905)47:1<45::aid-ddr6>3.0.co;2-u
    8 https://doi.org/10.1002/(sici)1098-2299(199908)47:4<178::aid-ddr4>3.0.co;2-l
    9 https://doi.org/10.1016/j.bcp.2004.03.026
    10 https://doi.org/10.1016/j.bmc.2008.01.002
    11 https://doi.org/10.1016/j.bmcl.2004.03.084
    12 https://doi.org/10.1016/j.bmcl.2004.11.044
    13 https://doi.org/10.1016/j.bmcl.2005.10.002
    14 https://doi.org/10.1016/j.bmcl.2006.04.074
    15 https://doi.org/10.1016/j.bmcl.2008.01.008
    16 https://doi.org/10.1016/s0165-6147(98)01179-1
    17 https://doi.org/10.1016/s0968-0896(01)00201-2
    18 https://doi.org/10.1016/s0968-0896(98)00007-8
    19 https://doi.org/10.1021/cr0682195
    20 https://doi.org/10.1021/jm00036a019
    21 https://doi.org/10.1021/jm00083a018
    22 https://doi.org/10.1021/jm00113a029
    23 https://doi.org/10.1021/jm00382a018
    24 https://doi.org/10.1021/jm0104318
    25 https://doi.org/10.1021/jm011049y
    26 https://doi.org/10.1021/jm0309654
    27 https://doi.org/10.1021/jm051268+
    28 https://doi.org/10.1021/jm061333v
    29 https://doi.org/10.1021/jm7014815
    30 https://doi.org/10.1021/jm990499b
    31 https://doi.org/10.1038/sj.bjp.0706272
    32 https://doi.org/10.1124/jpet.106.112250
    33 https://doi.org/10.1124/mol.104.009225
    34 https://doi.org/10.1161/01.hyp.0000144800.21037.a5
    35 https://doi.org/10.1165/rcmb.2003-0118oc
    36 https://doi.org/10.1165/rcmb.2004-0103oc
    37 https://doi.org/10.1172/jci27303
    38 https://doi.org/10.1517/13543776.16.10.1347
    39 https://doi.org/10.2174/138955705774933374
    40 https://doi.org/10.2174/1568026033392264
    41 https://doi.org/10.2174/15680266106061375
    42 https://doi.org/10.4049/jimmunol.172.12.7726
    43 schema:datePublished 2009-03
    44 schema:datePublishedReg 2009-03-01
    45 schema:description The selective, high affinity A(2B) adenosine receptor (AdoR) antagonists that were synthesized by several research groups should aid in determining the role of the A(2B) AdoR in inflammatory diseases like asthma or rheumatoid arthritis (RA) and angiogenic diseases like diabetic retinopathy or cancer. CV Therapeutics scientists discovered the selective, high affinity A(2B) AdoR antagonist 10, a 8-(4-pyrazolyl)-xanthine derivative [CVT-6883, K(i)(hA(2B)) = 22 nM; K(i)(hA(1)) = 1,940 nM; K(i)(hA(2A)) = 3,280; and K(i)(hA(3)) = 1,070 nM] that has favorable pharmacokinetic (PK) properties (t (1/2) = 4 h and F > 35% rat). Compound 10 demonstrated functional antagonism at the A(2B) AdoR (K(B) = 6 nM) and efficacy in a mouse model of asthma. In two phase 1 clinical trials, CVT-6883 was found to be safe, well tolerated, and suitable for once daily dosing. A second compound 20, 8-(5-pyrazolyl)-xanthine, has been nominated for development from Baraldi's group in conjunction with King Pharmaceuticals that has favorable A(2B) AdoR affinity and selectivity [K(i)(hA(2B)) = 5.5 nM; K(i)(hA(1)) > 1,000 nM; K(i)(hA(2A)) > 1,000; and K(i)(hA(3)) > 1,000 nM], and it has been demonstrated to be a functional antagonist. A third compound 32, a 2-aminopyrimidine, from the Almirall group has high A(2B) AdoR affinity and selectivity [K(i)(hA(2B)) = 17 nM; K(i)(hA(1)) > 1,000 nM; K(i)(hA(2A)) > 2,500; and K(i)(hA(3)) > 1,000 nM], and 32 has been moved into preclinical safety testing. Since three highly selective, high affinity A(2B) AdoR antagonists have been nominated for development with 10 (CVT-6883) being the furthest along in the development process, the role of the A(2B) AdoR in various disease states will soon be established.
    46 schema:genre research_article
    47 schema:inLanguage en
    48 schema:isAccessibleForFree true
    49 schema:isPartOf N127f21acb45a44a696b48a89ec6fd3e2
    50 Nc41cfd2124b240999fcb7f5cc3463ba2
    51 sg:journal.1035517
    52 schema:name Progress in the discovery of selective, high affinity A2B adenosine receptor antagonists as clinical candidates
    53 schema:pagination 21-29
    54 schema:productId N73d8e49e37884f11b9c7038dc6b5a8de
    55 Nb409474b25424a90a84daca975f6999b
    56 Ne6f930c1ef874497b6aca4dd5b1f950c
    57 Nec9cb0ea5f3a4dfcb50de1c25a242ec7
    58 Nfab99095c23d48deb9c48897d669b49d
    59 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036195632
    60 https://doi.org/10.1007/s11302-008-9119-x
    61 schema:sdDatePublished 2019-04-11T02:19
    62 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    63 schema:sdPublisher N47f981acb59f48bfb7834ce38a4ade12
    64 schema:url http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721775/
    65 sgo:license sg:explorer/license/
    66 sgo:sdDataset articles
    67 rdf:type schema:ScholarlyArticle
    68 N127f21acb45a44a696b48a89ec6fd3e2 schema:issueNumber 1
    69 rdf:type schema:PublicationIssue
    70 N47f981acb59f48bfb7834ce38a4ade12 schema:name Springer Nature - SN SciGraph project
    71 rdf:type schema:Organization
    72 N73d8e49e37884f11b9c7038dc6b5a8de schema:name readcube_id
    73 schema:value ac6b80eab621568b006300f20fb413a736788294a96f2fd5632c4f4a81890b61
    74 rdf:type schema:PropertyValue
    75 Nb409474b25424a90a84daca975f6999b schema:name nlm_unique_id
    76 schema:value 101250499
    77 rdf:type schema:PropertyValue
    78 Nc41cfd2124b240999fcb7f5cc3463ba2 schema:volumeNumber 5
    79 rdf:type schema:PublicationVolume
    80 Ncaab3614c2804d3da1391352540180e6 rdf:first sg:person.01031733402.53
    81 rdf:rest Nd85d617085b549379f0cbc1a90e52647
    82 Nce786085de33472da071758256adb336 schema:name Department of Bioorganic Chemistry, CV Therapeutics Inc., 3172 Porter Drive, Palo Alto, CA 94304 USA
    83 rdf:type schema:Organization
    84 Nd77a2b87e6904137a2a9a3d707c6c363 schema:name Department of Bioorganic Chemistry, CV Therapeutics Inc., 3172 Porter Drive, Palo Alto, CA 94304 USA
    85 rdf:type schema:Organization
    86 Nd85d617085b549379f0cbc1a90e52647 rdf:first sg:person.0706532554.35
    87 rdf:rest rdf:nil
    88 Ne6f930c1ef874497b6aca4dd5b1f950c schema:name dimensions_id
    89 schema:value pub.1036195632
    90 rdf:type schema:PropertyValue
    91 Nec9cb0ea5f3a4dfcb50de1c25a242ec7 schema:name doi
    92 schema:value 10.1007/s11302-008-9119-x
    93 rdf:type schema:PropertyValue
    94 Nfab99095c23d48deb9c48897d669b49d schema:name pubmed_id
    95 schema:value 18568423
    96 rdf:type schema:PropertyValue
    97 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    98 schema:name Medical and Health Sciences
    99 rdf:type schema:DefinedTerm
    100 anzsrc-for:1199 schema:inDefinedTermSet anzsrc-for:
    101 schema:name Other Medical and Health Sciences
    102 rdf:type schema:DefinedTerm
    103 sg:journal.1035517 schema:issn 1573-9538
    104 1573-9546
    105 schema:name Purinergic Signalling
    106 rdf:type schema:Periodical
    107 sg:person.01031733402.53 schema:affiliation Nce786085de33472da071758256adb336
    108 schema:familyName Kalla
    109 schema:givenName Rao V.
    110 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01031733402.53
    111 rdf:type schema:Person
    112 sg:person.0706532554.35 schema:affiliation Nd77a2b87e6904137a2a9a3d707c6c363
    113 schema:familyName Zablocki
    114 schema:givenName Jeff
    115 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706532554.35
    116 rdf:type schema:Person
    117 sg:pub.10.1007/bf03256599 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015558318
    118 https://doi.org/10.1007/bf03256599
    119 rdf:type schema:CreativeWork
    120 https://app.dimensions.ai/details/publication/pub.1074962052 schema:CreativeWork
    121 https://app.dimensions.ai/details/publication/pub.1083202690 schema:CreativeWork
    122 https://doi.org/10.1002/(sici)1098-2299(199905)47:1<45::aid-ddr6>3.0.co;2-u schema:sameAs https://app.dimensions.ai/details/publication/pub.1027056941
    123 rdf:type schema:CreativeWork
    124 https://doi.org/10.1002/(sici)1098-2299(199908)47:4<178::aid-ddr4>3.0.co;2-l schema:sameAs https://app.dimensions.ai/details/publication/pub.1050303514
    125 rdf:type schema:CreativeWork
    126 https://doi.org/10.1016/j.bcp.2004.03.026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027842212
    127 rdf:type schema:CreativeWork
    128 https://doi.org/10.1016/j.bmc.2008.01.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002966243
    129 rdf:type schema:CreativeWork
    130 https://doi.org/10.1016/j.bmcl.2004.03.084 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042039926
    131 rdf:type schema:CreativeWork
    132 https://doi.org/10.1016/j.bmcl.2004.11.044 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044434905
    133 rdf:type schema:CreativeWork
    134 https://doi.org/10.1016/j.bmcl.2005.10.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052793565
    135 rdf:type schema:CreativeWork
    136 https://doi.org/10.1016/j.bmcl.2006.04.074 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049359839
    137 rdf:type schema:CreativeWork
    138 https://doi.org/10.1016/j.bmcl.2008.01.008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017151471
    139 rdf:type schema:CreativeWork
    140 https://doi.org/10.1016/s0165-6147(98)01179-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017804473
    141 rdf:type schema:CreativeWork
    142 https://doi.org/10.1016/s0968-0896(01)00201-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024938586
    143 rdf:type schema:CreativeWork
    144 https://doi.org/10.1016/s0968-0896(98)00007-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009631944
    145 rdf:type schema:CreativeWork
    146 https://doi.org/10.1021/cr0682195 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053896200
    147 rdf:type schema:CreativeWork
    148 https://doi.org/10.1021/jm00036a019 schema:sameAs https://app.dimensions.ai/details/publication/pub.1055933249
    149 rdf:type schema:CreativeWork
    150 https://doi.org/10.1021/jm00083a018 schema:sameAs https://app.dimensions.ai/details/publication/pub.1055934504
    151 rdf:type schema:CreativeWork
    152 https://doi.org/10.1021/jm00113a029 schema:sameAs https://app.dimensions.ai/details/publication/pub.1055935638
    153 rdf:type schema:CreativeWork
    154 https://doi.org/10.1021/jm00382a018 schema:sameAs https://app.dimensions.ai/details/publication/pub.1055945659
    155 rdf:type schema:CreativeWork
    156 https://doi.org/10.1021/jm0104318 schema:sameAs https://app.dimensions.ai/details/publication/pub.1055946702
    157 rdf:type schema:CreativeWork
    158 https://doi.org/10.1021/jm011049y schema:sameAs https://app.dimensions.ai/details/publication/pub.1055946960
    159 rdf:type schema:CreativeWork
    160 https://doi.org/10.1021/jm0309654 schema:sameAs https://app.dimensions.ai/details/publication/pub.1055948364
    161 rdf:type schema:CreativeWork
    162 https://doi.org/10.1021/jm051268+ schema:sameAs https://app.dimensions.ai/details/publication/pub.1055950062
    163 rdf:type schema:CreativeWork
    164 https://doi.org/10.1021/jm061333v schema:sameAs https://app.dimensions.ai/details/publication/pub.1055950894
    165 rdf:type schema:CreativeWork
    166 https://doi.org/10.1021/jm7014815 schema:sameAs https://app.dimensions.ai/details/publication/pub.1055955364
    167 rdf:type schema:CreativeWork
    168 https://doi.org/10.1021/jm990499b schema:sameAs https://app.dimensions.ai/details/publication/pub.1055959662
    169 rdf:type schema:CreativeWork
    170 https://doi.org/10.1038/sj.bjp.0706272 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003683098
    171 rdf:type schema:CreativeWork
    172 https://doi.org/10.1124/jpet.106.112250 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006292491
    173 rdf:type schema:CreativeWork
    174 https://doi.org/10.1124/mol.104.009225 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049533071
    175 rdf:type schema:CreativeWork
    176 https://doi.org/10.1161/01.hyp.0000144800.21037.a5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023073291
    177 rdf:type schema:CreativeWork
    178 https://doi.org/10.1165/rcmb.2003-0118oc schema:sameAs https://app.dimensions.ai/details/publication/pub.1027367284
    179 rdf:type schema:CreativeWork
    180 https://doi.org/10.1165/rcmb.2004-0103oc schema:sameAs https://app.dimensions.ai/details/publication/pub.1041386031
    181 rdf:type schema:CreativeWork
    182 https://doi.org/10.1172/jci27303 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042274622
    183 rdf:type schema:CreativeWork
    184 https://doi.org/10.1517/13543776.16.10.1347 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046730538
    185 rdf:type schema:CreativeWork
    186 https://doi.org/10.2174/138955705774933374 schema:sameAs https://app.dimensions.ai/details/publication/pub.1069182582
    187 rdf:type schema:CreativeWork
    188 https://doi.org/10.2174/1568026033392264 schema:sameAs https://app.dimensions.ai/details/publication/pub.1069192897
    189 rdf:type schema:CreativeWork
    190 https://doi.org/10.2174/15680266106061375 schema:sameAs https://app.dimensions.ai/details/publication/pub.1069194448
    191 rdf:type schema:CreativeWork
    192 https://doi.org/10.4049/jimmunol.172.12.7726 schema:sameAs https://app.dimensions.ai/details/publication/pub.1076850170
    193 rdf:type schema:CreativeWork
     




    Preview window. Press ESC to close (or click here)


    ...